Monashee Investment Management LLC Makes New Investment in Lumexa Imaging Holdings, Inc. $LMRI

Monashee Investment Management LLC bought a new position in shares of Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 150,000 shares of the company’s stock, valued at approximately $2,775,000. Lumexa Imaging comprises about 1.6% of Monashee Investment Management LLC’s portfolio, making the stock its 23rd biggest holding.

A number of other institutional investors have also recently added to or reduced their stakes in LMRI. Assetmark Inc. bought a new stake in Lumexa Imaging during the 4th quarter worth approximately $36,000. Geode Capital Management LLC bought a new stake in Lumexa Imaging during the 4th quarter worth approximately $1,548,000. Seven Grand Managers LLC bought a new stake in Lumexa Imaging during the 4th quarter worth approximately $11,942,000. Goldman Sachs Group Inc. bought a new stake in shares of Lumexa Imaging in the 4th quarter valued at $18,870,000. Finally, TD Asset Management Inc bought a new stake in shares of Lumexa Imaging in the 4th quarter valued at $1,264,000.

Lumexa Imaging Stock Performance

NASDAQ:LMRI opened at $9.52 on Friday. The company has a fifty day moving average price of $8.85. Lumexa Imaging Holdings, Inc. has a 52 week low of $6.45 and a 52 week high of $19.45.

Insider Activity

In related news, Director Brett Brodnax bought 35,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The shares were bought at an average price of $7.25 per share, for a total transaction of $253,750.00. Following the transaction, the director directly owned 62,027 shares of the company’s stock, valued at approximately $449,695.75. The trade was a 129.50% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.70% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms have recently commented on LMRI. Weiss Ratings raised shares of Lumexa Imaging from a “sell (e-)” rating to a “sell (e)” rating in a research note on Monday, June 1st. Barclays reduced their price objective on shares of Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Lumexa Imaging has an average rating of “Moderate Buy” and an average target price of $16.00.

Lumexa Imaging Company Profile

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).